Med Pride Triple Antibiotic Ointment Recall
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Dabur India Limited recalls Med Pride Triple Antibiotic Ointment due to CGMP deviations observed during FDA inspection.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on August 1, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, fda, Drugs.
What Happened
Dabur India Limited initiated a voluntary recall of Med Pride Triple Antibiotic Ointment due to CGMP Deviations; deficiencies observed during FDA inspection. The recall is classified as Class II and affects products distributed US Nationwide.
Which Products Are Affected
Med Pride, Triple Antibiotic Ointment, Bacitracin Zinc (equivalent to 400 units), Neomycin Sulfate 5 mg, Polymixin B 5000 units, 0.9g packets, 144 packets per box, 130g, Manufactured for: Shield Line LLC, 59 Hook Road, Bayonne, NJ 07002 USA, Made in India. UPC 1 03 52410 30253 1. Affected lots: 011, 014, 015, 016, 017, 018, 019, 020, 021, 022, 026, Within Expiry. 3006 tubes affected. Recall number D-0641-2026.
What You Should Do
Consumers should check product lot numbers against the listed affected lots.
Why This Matters
This Class II recall involves 3006 tubes of ointment distributed nationwide due to manufacturing practice deviations.
Source
FDA recall number D-0641-2026, report date 20260624.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,008 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to August 1, 2026.
Frequently Asked Questions
Common questions about this FDA recall.